3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
11
Breast
4
Thoracic
3
Gastrointestinal
3
Dermatologic
3
Sarcoma
2
Other solid neoplasm
2
Head & Neck
2
Gynecologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
182
Ovarian Neoplasms
92
Carcinoma, Ovarian Epithelial
46
Fallopian Tube Neoplasms
35
Endometrial Neoplasms
29
Peritoneal Neoplasms
23
Stomach Neoplasms
18
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
11
Vulvar Neoplasms
9
Recurrence
9
Lung Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Pancreatic Neoplasms
7
Locally Advanced Cervical Cancer
7
Brenner Tumor
7
Uterine Neoplasms
6
Testicular Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasm Metastasis
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Sarcoma
5
Colonic Neoplasms
5
Breast Neoplasms
5
Vaginal Neoplasms
4
Triple Negative Breast Neoplasms
4
Teratoma
4
Small Cell Lung Carcinoma
4
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Cisplatin
×
Gynecologic
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled